NLS Pharmaceutics announces expected compliance with Nasdaq listing rules
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 15 2024
0mins
Should l Buy ?
Private Placement and Debt Agreement: NLS Pharmaceutics completed a private placement of 806,452 common shares and warrants for $3.2 million, along with a debt purchase agreement to issue convertible preferred shares in exchange for $4 million in debt relief.
Compliance with Nasdaq Requirements: The company believes it has regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements, as its shares have traded above $1.00 for ten consecutive days and it meets the $2.5 million equity threshold.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
